$16.65
0.130.79%
At close: Nov 11, 4:00 PM EST
$16.65
0.130.79%
Pre-Market: 4:15 AM EST
Xeris Biopharma Holdings Inc
XERSNASDAQ
Xeris Biopharma rose 129.3% from $7.26 to a 1-year high of $16.65, ahead of the S&P 500's +12.7%. Its worst day was Aug 6 (−9.2%), and its low came Mar 24 at $5.29.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Xeris Biopharma shares rose 12.8%, while the S&P 500 fell 0.0%.
+12.8% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
EPS of $0.06 beat the $0.04 estimate on $85.8M revenue (est. $84.2M); FY revenue guidance of $375.0M–$390.0M against the $370.3M consensus.
−1.6% · S&P 500 +0.1%
Xeris Biopharma closed at its lowest level of the year, 27.1% below where the year started.
−5.7% · S&P 500 −0.3%
EPS of $0.01 beat the $-0.01 estimate on $83.1M revenue (est. $80.0M); FY revenue guidance of $380.0M–$390.0M against the $383.7M consensus.
+4.1% · S&P 500 −0.3%
EPS of $0.00 missed the $0.01 estimate on $92.1M revenue (est. $90.4M); FY revenue guidance of $385.0M–$390.0M against the $386.0M consensus.
−9.2%, the year's worst day · S&P 500 −0.2%
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S.
−9.1% · S&P 500 −0.5%
Xeris Biopharma shares rose 11.6%, while the S&P 500 rose 0.7%.
+11.6% · S&P 500 +0.7%
EPS of $0.06 beat the $0.03 estimate on $106.3M revenue (est. $101.5M); FY revenue guidance of $1.0B.
+25.0%, the year's best day · S&P 500 −4.4%
Where it ended: a 1-year high close of $16.65 on Nov 12, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $0.07, revenue est. $119.0M).
Nothing in the past 12 months.
All XERS dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for XERS and SPY from Benzinga historical bars. Not investment advice.
